Alpha Cognition Inc. Common Stock
$8.80
$0.09 (+1.03%)
$8.34Day Range$8.94
Key Statistics
Market Cap
$191.65M
Shares Outstanding
21.8M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 9, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$8.61
Day High
$8.94
Day Low
$8.34
Volume
135.6K
VWAP
$8.72
Prev Close
$8.71
Transactions
--
Acc. Volume
--
About Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283671 employees1452 HUGHES RD., STE. 200, GRAPEVINE, TX, 76051(858) 344-4375IPO Jun 9, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001655923
- Composite FIGI
- BBG011CJPRD0
- Share Class FIGI
- BBG00L7TXNM1
- Ticker Root
- ACOG
- SIC Code
- 2836
About Alpha Cognition Inc. Common Stock (ACOG) Stock
Alpha Cognition Inc. Common Stock (ACOG) closed the 2026-09-15 session at $8.80, up 1.03% versus the previous close (+0.09). The stock opened at $8.61 and traded between $8.34 and $8.94 during that session. Session trading volume was 136K shares. The volume-weighted average price (VWAP) is $8.72.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
Alpha Cognition Inc. Common Stock has a market capitalization of $191.6 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. ACOG is listed on the XNAS exchange. The company employs approximately 71 people. Alpha Cognition Inc. Common Stock is headquartered in GRAPEVINE, TX. The recorded listing date is 2021-06-09.
On this page you can find market ACOG stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.